Evaluation of External Application of Varnyakar Lepa and Leech therapy in Vyanga(Melasma)
Phase 2
- Conditions
- Health Condition 1: L814- Other melanin hyperpigmentation
- Registration Number
- CTRI/2024/02/062768
- Lead Sponsor
- DrPratiksha Dundappa Talawar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Patients with signs & symptoms of Vyanga.
2 Signs & symptoms of Melasma.
Exclusion Criteria
1 Known case of any active skin malignancy
2 Pregnant woman
3 Patients suffering from all major systemic diseases IHD HIV Carcinoma
4 Patients having contagious infectious disease such as active tuberculosis Hepatitis B and C
5 Cases of burn & any skin allergy
6 Any lesion of other skin disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Varnyakar Lepa and leech therapy in melasma (L814) pigmentation reduction?
How does Jalukavacharan with Varnyakar Lepa compare to hydroquinone/tretinoin in melasma treatment efficacy?
Which biomarkers (e.g., tyrosinase, melanocortin-1 receptor) predict response to leech therapy in melasma?
What are the adverse event profiles of leech therapy combined with herbal lepas in skin hyperpigmentation?
Are there synergistic effects of hirudin-based therapies with azelaic acid or kojic acid in melasma management?